S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

NASDAQ:XENT - Intersect ENT Stock Price, Forecast & News

$26.76
-0.81 (-2.94 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$26.54
Now: $26.76
$27.93
50-Day Range
$23.30
MA: $25.70
$28.98
52-Week Range
$14.61
Now: $26.76
$35.87
Volume722,500 shs
Average Volume763,554 shs
Market Capitalization$843.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$108.47 million
Book Value$3.96 per share

Profitability

Net Income$-22,920,000.00

Miscellaneous

Employees393
Market Cap$843.34 million
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.


Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) released its earnings results on Friday, November, 1st. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.01. The medical equipment provider earned $24.06 million during the quarter, compared to analysts' expectations of $24.08 million. Intersect ENT had a negative return on equity of 34.19% and a negative net margin of 36.37%. The business's quarterly revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) earnings per share. View Intersect ENT's Earnings History.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Intersect ENT.

How can I listen to Intersect ENT's earnings call?

Intersect ENT will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109-109 million, compared to the consensus revenue estimate of $108.71 million.

What price target have analysts set for XENT?

9 equities research analysts have issued 12-month price objectives for Intersect ENT's stock. Their forecasts range from $20.00 to $40.00. On average, they expect Intersect ENT's share price to reach $27.25 in the next year. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Intersect ENT.

What is the consensus analysts' recommendation for Intersect ENT?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:
  • 1. Northland Securities analysts commented, "We are upgrading Intersect ENT to a Market Perform rating. We had downgraded the stock immediately after the Q1 report. The stock has reached our price target, hence the ratings change. We note though, the ratings change does not reflect a fundamental change in outlook, at least for now." (7/10/2019)
  • 2. According to Zacks Investment Research, "Over the past year, shares of Intersect ENT have underperformed the industry it belongs to. Escalating costs and expenses continue to weigh on the company’s margins. This apart, the pricing scenario is persistently tough for Intersect ENT. Strong competitors in the large medical device market also pose a tough challenge. On a positive note, within a short span of time, the SINUVA line of business has made a considerable progress with market access and field force balance. Within the company’s Propel line, Intersect ENT registered 10% growth in the top line during the fourth quarter 2018, driven by an expanded usage of Contour among both the current as well as the new physicians." (5/3/2019)
  • 3. BTIG Research analysts commented, "Intersect reported Q4 revenue in line with its preannouncement. Guidance of $123M-$127M (also given previously) remains just below the Street’s $127.2M but not surprising given some conservatism early in the year. The company will no longer guide SINUVA but is aware of Street estimates and will see how sales play out. The big surprise was operating expense guidance of $135-137M which was well above most estimates. We think shares will be pressured Tuesday. While a good portion of this increased spend will be R&D for a new drug-coated balloon, it is also clear that much of XENT’s growth is coming through head count. While Intersect will have significantly more data coming, we continue to remain cautious around reimbursement for SINUVA. We do not know what will happen with the re- proposed J-Code and we are not sure how many insurance companies will decide to pay more than once per year." (2/26/2019)

Has Intersect ENT been receiving favorable news coverage?

Press coverage about XENT stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intersect ENT earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Intersect ENT.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), COSTAMARE INC/SH (CMRE), Mimecast (MIME), Air Transport Services Group (ATSG), EOG Resources (EOG), Gilead Sciences (GILD), Netflix (NFLX) and AbbVie (ABBV).

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:
  • Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
  • Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
  • Ms. Christine R. Kowalski, Chief Operations Officer (Age 62)

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (4.97%), UBS Group AG (4.72%), Jennison Associates LLC (2.60%), Artisan Partners Limited Partnership (2.58%), State Street Corp (2.26%) and Broadfin Capital LLC (2.00%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard E Kaufman, Robert H Binney, Jr and Susan P Stimson. View Institutional Ownership Trends for Intersect ENT.

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, Broadfin Capital LLC, Schonfeld Strategic Advisors LLC, Candriam Luxembourg S.C.A., State Street Corp, State of New Jersey Common Pension Fund D and New York State Common Retirement Fund. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Robert H Binney, Jr and Susan P Stimson. View Insider Buying and Selling for Intersect ENT.

Which institutional investors are buying Intersect ENT stock?

XENT stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Jennison Associates LLC, Credit Suisse AG, Goldman Sachs Group Inc., Parkman Healthcare Partners LLC, UBS Group AG, Fairmount Funds Management LLC and Kopp Family Office LLC. View Insider Buying and Selling for Intersect ENT.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $26.76.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $843.34 million and generates $108.47 million in revenue each year. The medical equipment provider earns $-22,920,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.View Additional Information About Intersect ENT.

What is Intersect ENT's official website?

The official website for Intersect ENT is http://www.intersectent.com/.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  387 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  668
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel